MT 7117Alternative Names: MT-7117
Latest Information Update: 01 Sep 2016
At a glance
- Originator Mitsubishi Tanabe Pharma Corporation
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Autoimmune disorders
Most Recent Events
- 06 Jul 2016 Preclinical trials in Autoimmune disorders in Japan prior to July 2016 (unspecified route)
- 06 Jul 2016 Mitsubishi Tanabe Pharma plans a phase I trial in Healthy volunteers in United Kingdom (NCT02834442)
- 01 Jul 2016 Phase-I clinical trials in Autoimmune disorders (In volunteers) in United Kingdom (unspecified route) (NCT02834442)